HER3-DXd

Phase 2Biologic

Daiichi Sankyo

HER3-DXd is one of 123 biologic programs targeting Esophageal Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

122

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Gastroesophageal AdenocarcinomaRecruiting

Carcinoma, Non-Small-Cell LungRecruiting

Esophageal AdenocarcinomaPhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Gastroesophageal AdenocarcinomaPreclinical

Recruiting

Carcinoma, Non-Small-Cell LungPreclinical

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

72 2

HER3-DXd

Daiichi Sankyo

Phase 2

3 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Imjudo

AstraZeneca

Preclinical

5 5

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 6

Remeron

OOrganon and Co

Preclinical

1 7

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Vidaza

1 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Non-Small Cell Lung Cancer

NCT03260491

Q2 2027

Phase 1Active, not recruiting

Non-Small Cell Lung Cancer

NCT04676477

Q4 2028

Phase 2Recruiting

Locally Advanced or Metastatic Solid Tumors

NCT06172478

Q3 2030

PreclinicalRecruiting

Gastroesophageal Adenocarcinoma

NCT06445972

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT03260491·312 enrolled

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06731907·90 enrolled

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT04676477·246 enrolled

ESS1 trial

Medical Access Program for Patritumab Deruxtecan

No longer available· Daiichi Sankyo logo

Daiichi Sankyo··NCT06099639

Locally Advanced or Metastatic Solid Tumors1 trial

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT06172478·740 enrolled

Gastroesophageal Adenocarcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06445972·210 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT04165070·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for HER3-DXd. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HER3-DXd compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HER3-DXd. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daiichi Sankyo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Daiichi Sankyo

HER3-DXd

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2028

Q3 2030

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

ESS1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Gastroesophageal Adenocarcinoma1 trial

Carcinoma, Non-Small-Cell Lung1 trial

References

Drug Info

Quick Facts

Related News